Fluticasone
| Structural formula | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||
| General | ||||||||||
| Non-proprietary name | Fluticasone | |||||||||
| Molecular formula |
|
|||||||||
| External identifiers / databases | ||||||||||
|
||||||||||
| Drug information | ||||||||||
| ATC code | ||||||||||
| properties | ||||||||||
| Molar mass | ||||||||||
| safety instructions | ||||||||||
|
||||||||||
| Toxicological data | ||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||
Fluticasone is a synthetic drug from the group of glucocorticoids .
properties
Fluticasone is a synthetic and fluorinated glucocorticoid. The esters fluticasone propionate and fluticasone furoate are used medicinally . Fluticasone propionate is a colorless solid that is a white to almost white powder. The molecule is very lipophilic . Therefore, it is almost insoluble in water , but it quickly gets into cells and binds to cytosolic glucocorticoid receptors . The active substance is metabolized by the enzyme CYP3A4 .
use
Fluticasone is an anti-inflammatory , antiallergic and immunosuppressive agent that is used, among other things, to treat bronchial asthma and obstructive pulmonary diseases . Other areas of indication include a. allergic rhinitis , nasal polyps and dermatoses .
Side effects
The most common adverse effects are Candida albicans infections of the lining of the mouth and throat ( oral thrush ). Upper respiratory infections, hoarseness, pneumonia in COPD patients, headaches , fatigue, vulnerability of the skin and bruises are also frequently observed. In order to avoid undesirable effects on the mucous membrane of the mouth and throat, the mouth should be rinsed with water or something to eat after inhalation. Very rare undesirable effects include Quincke's edema , allergies , Cushing's syndrome , inhibition of adrenal function , growth retardation in children and adolescents, decreased bone density , glaucoma , hyperglycaemia, anxiety, sleep disorders, behavior changes, and paradoxical bronchospasm .
Dosage forms and trade names
Fluticasone is available as a nasal spray , powder inhalation , suspension for inhalation (metered dose aerosol), cream and ointment . It has been approved in Switzerland since 1993.
- Monopreparations : Axotide (CH), Avamys (EU), Flutide (D), Nasofan (CH), Cutivate (AT, CH).
- Combination preparations : with Salmeterol : Atmadisc (D), Rolenium (D), Seretide (D, CH, A), Viani (D, A), Airflusal (D, A); with formoterol : flutiform (D); with azelastine : Dymista (D, USA, LT); with Vilanterol : Relvar Revinty (D, CH)
literature
- B. Jarvis, D. Faulds: Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages <or = 500 microg / day in adults and adolescents with mild to moderate asthma. In: Drugs. 57 (5), 1999, pp. 769-803. PMID 10353302
- M. Johnson: The anti-inflammatory profile of fluticasone propionate. In: Allergy. 50 (23), 1995, pp. 11-14. PMID 7604948
- GM Keating, PL McCormack: Salmeterol / fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. In: Drugs. 67 (16), 2007, pp. 2383-2405. PMID 17983257
- NA Reynolds, KA Lyseng-Williamson, LR Wiseman: Inhaled salmeterol / fluticasone propionate: a review of its use in asthma. In: Drugs. 65 (12), 2005, pp. 1715-1734. PMID 16060707
- CM Spencer, B. Jarvis: Salmeterol / fluticasone propionate combination. In: Drugs. 57 (6), 1999, pp. 933-940. PMID 10400406
- AG Staresinic, CA Sorkness: Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. In: Expert Opin Pharmacother. 1 (6), 2000, pp. 1227-1244. PMID 11249490
- Avamys, Summary of Product Characteristics (PDF; 440 kB), as of December 2012, European Medicines Agency.
Individual evidence
- ↑ a b c Data sheet Fluticasone propionate, ≥98% (HPLC), powder from Sigma-Aldrich , accessed on March 21, 2013 ( PDF ).
